公开(公告)号：US10900966B2

公开(公告)日：2021-01-26

申请号：US16281122

申请日：2019-02-21

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Jing-Rong Wang ,  Weina Gao ,  Leefong Yau ,  Hao Huang ,  Qiong Meng ,  Tiantian Tong ,  Zhi-Hong Jiang

IPC: G01N33/564 ,  G01N33/48 ,  G01N1/40 ,  G01N30/08 ,  G01N30/60 ,  B01L3/00 ,  G01N30/72 ,  G01N30/88

Abstract: The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed.

公开(公告)号：US10688105B2

公开(公告)日：2020-06-23

申请号：US15644945

申请日：2017-07-10

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Kam Wai Wong ,  Yuen Kwan Law ,  Cong Ling Qiu

IPC: A61K31/185 ,  A61K31/495 ,  A61K31/56 ,  A61K31/519 ,  A61K31/573 ,  A61K31/165 ,  A61K31/42 ,  A61K45/06 ,  A61K31/635 ,  A61K31/19 ,  A61K39/00 ,  A61K31/365

Abstract: A method for treating a subject suffering from refractory rheumatoid arthritis includes the step of administering an effective amount of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof to the subject. Also is a method for inducing autophagy in a synovial fibroblast, and a method of inducing calcium mobilization in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA) in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.

公开(公告)号：US10322097B2

公开(公告)日：2019-06-18

申请号：US14971153

申请日：2015-12-16

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Thomas Efferth ,  Su-Wei Xu ,  Sami Hamdoun ,  Liang Liu

IPC: A61K31/19 ,  A61K31/337 ,  A61K31/553 ,  A61K31/704 ,  A61K31/7048 ,  A61K33/24

Abstract: A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.

公开(公告)号：US10220064B2

公开(公告)日：2019-03-05

申请号：US15345842

申请日：2016-11-08

Applicant: Macau University of Science and Technology

Inventor： Hua Zhou ,  Quanbing Han ,  Yihan Zuo ,  Liang Liu ,  Ruiqi Yue

IPC: A61K36/258 ,  A61K31/715

Abstract: Methods of treating a subject suffering from an ischemic condition and of preventing an ischemia-reperfusion injury in a subject suffering from an ischemic condition, particularly, but not exclusively ischemic heart disease and the subject is in particular a human, includes administering an effective amount of a carbohydrate composition extracted from Panax ginseng to the subject. The carbohydrate composition of the present invention extracted from Panax ginseng shows exceptional cardio-protective effect and, thus, provides a highly advantageous and highly promising treatment option for treatment of ischemic conditions and prevention of ischemia-reperfusion injury. The present invention further provides a method of protecting cells against hypoxia and reoxygenation induced cell death. Still further, the present invention provides a carbohydrate composition extracted from Panax ginseng and a pharmaceutical formulation comprising it.

公开(公告)号：US09955676B2

公开(公告)日：2018-05-01

申请号：US14620141

申请日：2015-02-11

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Ting Li ,  Kam Wai Wong ,  Zhihong Jiang ,  Hua Zhou

IPC: A01K67/027 ,  C12N15/00 ,  A61K49/00 ,  G01N33/573 ,  A61K31/70 ,  G01N33/574

CPC classification number: A01K67/0278 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0368 ,  A61K49/0008 ,  G01N33/573 ,  G01N33/574 ,  G01N2333/91215 ,  G01N2800/102 ,  G01N2800/44

Abstract: The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-βC46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-β protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-β. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-βC46A mutants.

公开(公告)号：US09744145B1

公开(公告)日：2017-08-29

申请号：US15406798

申请日：2017-01-16

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Lai-Han Elaine Leung ,  Xiao-Jun Yao ,  Run-Ze Li

IPC: A61K31/18

CPC classification number: A61K31/18

Abstract: This invention provides a method of treating lung cancer including administering a therapeutically effective amount of a compound of 0089-0022 formula I to a subject in need thereof. The compound activates pyruvate kinase M2 isoform (PKM2) to treat the lung cancer. In one example, the lung cancer is Non-Small Cell Lung Cancer (NSCLC).

公开(公告)号：US20170135979A1

公开(公告)日：2017-05-18

申请号：US14940406

申请日：2015-11-13

Applicant: Macau University of Science and Technology

Inventor： Xiao Jun Yao ,  Lai Han Leung ,  Lian Xiang Luo ,  Liang Liu

IPC: A61K31/343

CPC classification number: A61K31/343

Abstract: The present invention relates to the administration of a novel compound advantageously efficacious as PDEδ inhibitor and its effects on subjects with cancer. More specifically, the present invention is directed to a method for administering a compound having favorable geometric properties for interacting with the PDEδ prenyl-binding pocket, namely has certain structural components such as a three-cyclic backbone and at least one benzoyl-moiety in a side chain having at least two substituents containing highly electronegative atoms and being linked to the backbone via an aliphatic chain, for treating a subject suffering from a disease such as cancer, in particular non-small-cell lung cancer. The presence of said structural components particularly contributes to an advantageous interaction with PDEδ, in particular with amino acids deep in the binding pocket. The present invention further provides a method to target tumor cells harboring an RAS gene mutation as well as pharmaceutical compositions comprising said compound.

公开(公告)号：US09597299B2

公开(公告)日：2017-03-21

申请号：US14624574

申请日：2015-02-17

Applicant: Macau University of Science and Technology

Inventor： Lai-Han Leung ,  Xing-Xing Fan ,  Liang Liu ,  Zebo Jiang

IPC: A61K31/661 ,  A61K31/09

CPC classification number: A61K31/09

Abstract: The present invention relates to a method for treating gefitinib-resistant non-small-cell lung cancer (NSCLC) comprising administering an effective amount of a resveratrol analog, (Z)3,4,5,4′-tetramethoxystilbene (TMS), to a subject in need thereof. The present invention also relates to a method for inducing apoptosis in gefitinib-resistant NSCLC cells comprising contacting the resveratrol analog to the cells at an effective amount. The present methods are mediated by different signaling pathways connected to cell proliferation and differentiation such as mTOR, JNK, and certain EGFR phosphorylated tyrosine kinase.

公开(公告)号：US09561221B2

公开(公告)日：2017-02-07

申请号：US14985417

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Liang Liu ,  Jingrong Wang

IPC: A61K31/4725 ,  A61K31/4745 ,  A61K31/4748

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

公开(公告)号：US09364469B1

公开(公告)日：2016-06-14

申请号：US14925996

申请日：2015-10-29

Applicant: Macau University of Science and Technology

Inventor： Lai-Han Leung ,  Xiao-Jun Yao ,  Kam Wai Wong ,  Liang Liu ,  Xi Chen

IPC: A61K31/4439

CPC classification number: A61K31/4439

Abstract: The present invention discloses a method of treating gefitinib-resistant non-small-cell lung cancer, comprising administering an effective amount of D561-0775. A pharmaceutical composition comprising D561-0775 admixed with a pharmaceutical carrier for treating Gefitinib-resistant non-small-cell lung cancer is also disclosed therein.

Abstract translation: 本发明公开了一种治疗耐吉非替尼的非小细胞肺癌的方法，包括给予有效量的D561-0775。 还公开了包含D561-0775的药物组合物，其与药物载体混合以治疗吉非替尼耐药性非小细胞肺癌。